204 related articles for article (PubMed ID: 22203494)
21. Expression of serine and glycine-related enzymes in phyllodes tumor.
Kwon JE; Kim DH; Jung WH; Koo JS
Neoplasma; 2014; 61(5):566-78. PubMed ID: 25030440
[TBL] [Abstract][Full Text] [Related]
22. Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression.
Ang MK; Ooi AS; Thike AA; Tan P; Zhang Z; Dykema K; Furge K; Teh BT; Tan PH
Breast Cancer Res Treat; 2011 Sep; 129(2):319-29. PubMed ID: 20945089
[TBL] [Abstract][Full Text] [Related]
23. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast.
Tsang JYS; Hui YK; Lee MA; Lacambra M; Ni YB; Cheung SY; Wu C; Kwong A; Tse GMK
Sci Rep; 2018 Mar; 8(1):3881. PubMed ID: 29497099
[TBL] [Abstract][Full Text] [Related]
24. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
Esposito NN; Mohan D; Brufsky A; Lin Y; Kapali M; Dabbs DJ
Arch Pathol Lab Med; 2006 Oct; 130(10):1516-21. PubMed ID: 17090194
[TBL] [Abstract][Full Text] [Related]
25. Phyllodes tumor of the breast. A cytohistologic study of 80 cases.
Bhattarai S; Kapila K; Verma K
Acta Cytol; 2000; 44(5):790-6. PubMed ID: 11015981
[TBL] [Abstract][Full Text] [Related]
26. p53 expression in phyllodes tumours is associated with histological features of malignancy but does not predict outcome.
Feakins RM; Mulcahy HE; Nickols CD; Wells CA
Histopathology; 1999 Aug; 35(2):162-9. PubMed ID: 10460662
[TBL] [Abstract][Full Text] [Related]
27. Expression of autophagy-related proteins in phyllodes tumor.
Kim SK; Jung WH; Koo JS
Int J Clin Exp Pathol; 2013; 6(10):2145-56. PubMed ID: 24133593
[TBL] [Abstract][Full Text] [Related]
28. mRNA expression profiling of phyllodes tumours of the breast: identification of genes important in the development of borderline and malignant phyllodes tumours.
Jones AM; Mitter R; Poulsom R; Gillett C; Hanby AM; Tomlinson IP; Sawyer EJ;
J Pathol; 2008 Dec; 216(4):408-17. PubMed ID: 18937276
[TBL] [Abstract][Full Text] [Related]
29. In phyllodes tumour of the breast expression of c-kit but not of ALDH1A1 is associated with adverse clinico-pathological features.
Chougule A; Bal A; Das A; Kohli PS; Singh G
Virchows Arch; 2016 Dec; 469(6):651-658. PubMed ID: 27696244
[TBL] [Abstract][Full Text] [Related]
30. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
Kim GE; Kim NI; Park MH; Lee JS
Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
[TBL] [Abstract][Full Text] [Related]
31. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
[TBL] [Abstract][Full Text] [Related]
32. Malignant Phyllodes of Breast.
Yom CK
Adv Exp Med Biol; 2021; 1187():601-612. PubMed ID: 33983602
[TBL] [Abstract][Full Text] [Related]
33. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
Chen WH; Cheng SP; Tzen CY; Yang TL; Jeng KS; Liu CL; Liu TP
J Surg Oncol; 2005 Sep; 91(3):185-94. PubMed ID: 16118768
[TBL] [Abstract][Full Text] [Related]
34. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
35. The clinical features and prognosis of phyllodes tumors: a single institution experience in Taiwan.
Lin CC; Chang HW; Lin CY; Chiu CF; Yeh SP
Int J Clin Oncol; 2013 Aug; 18(4):614-20. PubMed ID: 22773245
[TBL] [Abstract][Full Text] [Related]
36. Local Recurrence of Benign, Borderline, and Malignant Phyllodes Tumors of the Breast: A Systematic Review and Meta-analysis.
Lu Y; Chen Y; Zhu L; Cartwright P; Song E; Jacobs L; Chen K
Ann Surg Oncol; 2019 May; 26(5):1263-1275. PubMed ID: 30617873
[TBL] [Abstract][Full Text] [Related]
37. CD34, CD117, and actin expression in phyllodes tumor of the breast.
Chen CM; Chen CJ; Chang CL; Shyu JS; Hsieh HF; Harn HJ
J Surg Res; 2000 Dec; 94(2):84-91. PubMed ID: 11104647
[TBL] [Abstract][Full Text] [Related]
38. Borderline and malignant phyllodes tumors display similar promoter methylation profiles.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
Virchows Arch; 2009 Dec; 455(6):469-75. PubMed ID: 19924440
[TBL] [Abstract][Full Text] [Related]
39. [Histologic classification and prognosis factors in phyllodes tumors of breast].
Jia C; Mei F; Liu JY; Zhao HM; Lei YT; Su J; Huang SS; Zheng J; You JF
Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):14-19. PubMed ID: 28072970
[No Abstract] [Full Text] [Related]
40. Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast.
Spanheimer PM; Murray MP; Zabor EC; Stempel M; Morrow M; Van Zee KJ; Barrio AV
Ann Surg Oncol; 2019 Jul; 26(7):2136-2143. PubMed ID: 30783853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
